Celltrion Group, an Incheon, South Korea-based bio/pharmaceutical company, has announced plans to invest KRW 700 billion ($478 million) to expand a former Lilly active pharmaceutical ingredient (API) manufacturing facility in the US. Celltrion completed the acquisition of the former Lilly facility in Branchburg, New Jersey, last month (November 2025).   

The company plans to expand production capacity at the US facility in a phased expansion. Phase 1 of the expansion will add three 11,000-L bioreactors. Phase 2 will add three more 11,000-L bioreactors. In sum, the company is adding additional capacity of 66,000 L, resulting in 132,000 L of total production capacity at the site. 

The company also says that in response to future tariff measures and further pipeline expansion, the company will also consider constructing an additional manufacturing facility using available land within the US site. 

The announcement was made via the Data Analysis, Retrieval, and Transfer (DART) system, a public online portal run by South Korea’s Financial Supervisory Service (FSS) for corporate filings and disclosures.  

Source: Celltrion Group